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Our previous study showed that enhanced carbonyl stress is closely related to schizophrenia. The
endogenous secretory receptor for advanced glycation end-products (esRAGE) is a splice variant of the
AGER gene and is one of the soluble forms of RAGE. esRAGE is considered to be a key molecule for
alleviating the burden of carbonyl stress by entrapping advanced glycation end-products (AGEs). In the
current study, we conducted genetic association analyses focusing on AGER, in which we compared 212
schizophrenic patients to 214 control subjects. We also compared esRAGE levels among a subgroup of
104 patients and 89 controls and further carried out measurements of total circulating soluble RAGE
(sRAGE) in 25 patients and 49 healthy subjects. Although the genetic association study yielded incon-
clusive results, multiple regression analysis indicated that a speciﬁc haplotype composed of rs17846798,
rs2071288, and a 63 bp deletion, which were in perfect linkage disequilibrium (r2 ¼ 1), and rs2070600
(Gly82Ser) were signiﬁcantly associated with a marked decrease in serum esRAGE levels. Furthermore,
compared to healthy subjects, schizophrenia showed signiﬁcantly lower esRAGE (p ¼ 0.007) and sRAGE
(p ¼ 0.03) levels, respectively. This is the ﬁrst study to show that serum esRAGE levels are regulated by a
newly identiﬁed speciﬁc haplotype in AGER and that a subpopulation of schizophrenic patients are more
vulnerable to carbonyl stress.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).roducts; RAGE, receptor for




Inc. This is an open access article u1. Introduction
Carbonyl stress is an abnormal metabolic state that results from
either increased production of reactive carbonyl compounds (RCOs)
by oxidation of carbohydrates, or decreased detoxiﬁcation of RCOs
[1]. Advanced glycation end products (AGEs) are generated as ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mental studies in animals and humans have implicated increased
AGEs in a variety of diseases including diabetes mellitus (DM),
chronic kidney disease (CKD), cardiovascular diseases (CVD), Alz-
heimer's disease (AD), and schizophrenia [2e6]. The glyoxalase
system detoxiﬁes a-oxoaldehydes leading to inhibition of the for-
mation of some AGEs, thus alleviating the unfavorable physiolog-
ical effects induced by these AGEs. Pyridoxamine, one of the three
forms of vitamin B6, can also inhibit the formation of AGEs.
Exhaustion of pyridoxamine eventually leads to decreases in the
two other forms of vitamin B6, namely pyridoxine and pyridoxal.
Neither of the latter two isoforms shows therapeutic beneﬁt.
The receptor for advanced glycation end-products (RAGE),
which was ﬁrst characterized in 1992 [7], belongs to the immu-
noglobulin super family and is ubiquitously expressed at low levels
in human tissues, except in the lung. RAGE is a membrane bound
receptor with many ligands, including AGEs, S100/calgranulins,
amphoterin, and A-b [7e10]. Binding of these ligands to RAGE in-
duces intracellular signal transduction, leading to the activation of
several proinﬂammatory pathways. Thus RAGE acts, at least in part,
as an activator of carbonyl stress and has been implicated in various
disorders, including Alzheimer's disease [11e13]. Endogenous
secretory RAGE (esRAGE) is one of the circulating forms of RAGE
(sRAGE) and is generated as a splice variant of advanced glycosyl-
ation end product-speciﬁc receptor (AGER), the gene that encodes the
RAGE protein. esRAGE has no intracellular signal transduction
properties due to a loss of the transmembrane domain [14,15]. To
date, a number of studies have demonstrated that esRAGE exerts a
protective role in many diseases associated with RAGE [16e18].
esRAGE is thus considered to protect against the formation of AGEs
and act as a key inhibitor of carbonyl stress. This article focused on
esRAGE as a possible critical regulator of carbonyl stress and
investigated the relationship between variants in AGER and
schizophrenia through comprehensive mutation screening of AGER.
In addition, we compared serum esRAGE levels and sRAGE levels in
schizophrenia and controls taking into consideration functional
variants in AGER. By using direct-sequencing methods, we identi-
ﬁed functional variants of AGER that were associated with marked
decreases in serum esRAGE levels. Additionally, we found signiﬁ-
cantly lower esRAGE and sRAGE levels in schizophrenic patients
compared to those in control subjects. Our ﬁndings may explain
why a subpopulation of schizophrenia may be vulnerable to
carbonyl stress.
2. Materials and methods
2.1. Subjects
In this study, 212 schizophrenics (123 males and 89 females)
and 214 age and sex matched healthy controls (135 males and 79
females) were recruited to evaluate the association between ge-
netic variants in AGER and schizophrenia. Diagnoses were made
according to the Diagnostic and Statistical Manual of Mental Dis-
orders, 4th Edition, Text Revision (DSM-IV-TR) and were conﬁrmed
by at least two experienced psychiatrists. Control subjects were
recruited from among hospital staff and company employees who
were documented to be free from mental illness, based on brief
interviews. Next, 193 subjects were selected that were composed of
104 patients (56 males and 48 females) and 89 controls (31 males
and 58 females), all of whom provided serum samples in sufﬁcient
amount for the measurement of esRAGE levels. Finally, we
measured sRAGE levels in the serum of 25 patients suffering from
schizophrenia (19 males and 6 females) and in 49 control subjects
(16 males and 33 females). The other unselected patients and
controls could not be examined in the ﬁnal analysis because ofinsufﬁcient or no remaining serum sample. All participants pro-
vided written informed consent, and the study protocols were
approved by the ethics committees of all participating institutions.
2.2. Genotyping
All coding regions and introns, as well as the 50 upstream region
of AGER, were examined by direct sequencing of polymerase chain
reaction (PCR) products. Detailed information on the PCR ampliﬁ-
cation conditions is available from the authors upon request. The
PCR products were sequenced using a BigDye Terminator Cycle
Sequencing Reaction Kit (Applied Biosystems, Foster City, Califor-
nia) and an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
2.3. Measurement of serum esRAGE and sRAGE levels
Fresh serum samples were obtained from all participants over
the same time schedule and were stored at 80 C until mea-
surement. Serum esRAGE levels weremeasured using the sandwich
Enzyme-Linked Immuno Sorbent Assay (sandwich ELISA) that
employs an esRAGE-speciﬁc antibody against the unique 16-
amino-acid peptide C-terminal of esRAGE. All measurements
were conducted at the Department of Biochemistry and Molecular
Vascular Biology, Kanazawa University Graduate School of Medical
Sciences. Serum sRAGE levels were determined by using a human
sRAGE ELISA kit (Quantikine® ELISA Human RAGE Cat#DRG00 R&D
Systems).
2.4. Statistical analysis
Datawere analyzed using SPSS version 20.0 software (IBM, USA)
and GraphPad Prism 6 (GraphPad Software, USA). For the associa-
tion study, Fisher's exact test was used when comparing allele
frequency for all variants. Corrected p-values less than 0.002 (0.05/
28 variants) were considered statistically signiﬁcant. Multiple
regression analysis was conducted to determine the factors regu-
lating serum esRAGE and sRAGE levels. In these analyses, signiﬁ-
cance was deﬁned as p < 0.05.
3. Results
We ﬁrst determined the presence of AGER variants in schizo-
phrenic and control subjects. The demographics of the genotyped
subjects are summarized in Supplementary Table 1. Genotyping
analysis identiﬁed 28 variants of the AGER gene, including 8 novel
changes (Supplementary Table 2). All variants were in Hardy
Weinberg Equilibrium in control subjects. Unfortunately, no AGER
variants were signiﬁcantly associated with schizophrenia as
deﬁned by the corrected p-value.
Next, we investigated the association between variants in AGER
and serum esRAGE levels. The demographics of the subjects
examined in this esRAGE analysis are shown in (Supplementary
Table 3). As mentioned in the materials and methods section, a
total of 193 subjects were selected from the genetic association
study for this analysis. The other unselected subjects were not
included because there was insufﬁcient serum sample available for
analysis. Thus, the subjects of this analysis were composed of 104
schizophrenic patients (103 schizophrenia, 1 schizoaffective disor-
der) and 89 controls.
To identify functional variants in AGER associated with serum
esRAGE levels, we compared the esRAGE levels of subjects carrying
the homozygous major allele with those of heterozygous or ho-
mozygous carriers of the minor allele, for all variants detected in
AGER. Consistent with a previous study, we found that subjects
harboring the mutated genotype (GA or AA: Glycine/Serine or
Fig. 1. Marked decreases in serum esRAGE levels with rs2070600 Top: Schematic outline of the AGER gene. AGER exon numbers are marked as boxes. ATG and TGA denote start and
stop codons, respectively. TM, transmembrane domain. The position and nature of the variants of haplotype 1 composed of rs17846798, rs2071288, and a 63bp deletion, and of
rs2070600 are shown. A: Serum levels of esRAGE in schizophrenic and control individuals of the indicated genotype of rs2070600. (GG vs. GA, Schizophrenia p ¼ 0.02, Control
p ¼ 0.04; GG vs. AA, Schizophrenia p < 0.01) B: Serum levels of esRAGE in schizophrenic and control individuals of the indicated genotype of haplotype 1. Schizophrenia wild type
(wt) vs. mutant (mt) p < 0.01; control wt vs. mt p < 0.01). Error bars indicate standard deviation (SD). *p < 0.05, **p < 0.01.
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association with lower serum esRAGE levels, compared with car-
riers of the wild type genotype (GG: Glycine/Glycine) (Fig. 1A, GG
vs. GA, Schizophrenia p ¼ 0.02, Controls p ¼ 0.04; GG vs. AA,
Schizophrenia p < 0.01, Controls GG vs. AA was not applicable to
statistical analysis because only one subject had AA). Additionally,
we newly found that a speciﬁc haplotype (haplotype 1) composed
of the SNPs rs17846798 (intron 6, variant 15) and rs2071288 (intron
9, variant 25) and a 63 bp deletion (promoter, variant 3) were in
perfect linkage disequilibrium (r2 ¼ 1) and were also strongly
associated with a marked decrease in serum esRAGE levels (Fig. 1B,
wild type vs. mutated genotype, Schizophrenia p < 0.01; Controls
p < 0.01). Thus, similar trends of association were observed in both
schizophrenic patients and control subjects (Fig. 1).
Next, we compared the serum esRAGE levels of the subjects (104
schizophrenics and 89 controls). Prior to this analysis, we evaluated
the correlation between age and esRAGE in control individuals, but
no signiﬁcant association was found (p ¼ 0.71). In addition, no sex
difference in esRAGE levels was found in control subjects (p¼ 0.75).
We also conﬁrmed that a daily dose of antipsychotics did not
signiﬁcantly correlate with esRAGE levels (p ¼ 0.23). Most impor-
tantly, there was no signiﬁcant difference between groups
regarding the proportion of subjects harboring AGER risk variants
(Supplementary Table 3). We therefore conducted a direct com-
parison (Mann Whitney test) of esRAGE levels between theschizophrenia and control groups without adjustment for age and
sex, in spite of the fact that age and sex were signiﬁcantly different
in both groups (Supplementary Table 3). This analysis identiﬁed
signiﬁcantly decreased serum esRAGE levels in schizophrenic pa-
tients relative to those of control samples (Fig. 2).
To further investigate the implication of the decreased esRAGE
levels shown in schizophrenia for enhanced carbonyl stress, we
measured serum sRAGE levels in both groups. In these analyses, our
choice of subjects was restricted to 25 patients and 49 controls
from the esRAGE analysis because there was too little, or no serum
available from the other subjects for examination. The de-
mographics of the participants in these analyses are summarized in
Supplementary Table 4. These analyses indicated signiﬁcantly
lower sRAGE in the serum of patients suffering from schizophrenia
as compared to those in the serum of control individuals (Fig. 3A).
In addition, serum esRAGE levels was reproducibly decreased in
schizophrenia. (Schizophrenia: 238.4 ± 133.6 pg/ml, Control:
310.4 ± 128.8 pg/ml, p ¼ 0.02). Furthermore, we found that serum
esRAGE levels accounted for approximately 40% of the serum
sRAGE levels in both groups (Fig. 3B).
Lastly, we performed multiple regression analysis to determine
the factors that exerted the most robust effect on serum esRAGE
and sRAGE levels in all subjects.We included independent variables
such as age, sex, diagnosis, genotype of glyoxalase I (GLO1, a key
enzyme for detoxifying carbonyl compounds), GLO1 enzymatic
Fig. 2. A signiﬁcant decrease in serum esRAGE levels was shown in schizophrenia.
esRAGE levels were measured in schizophrenia (N ¼ 104) and control (N ¼ 89) in-
dividuals (Schizophrenia: 262.1 ± 141.8 pg/ml, control: 301.7 ± 122.0 pg/ml,
p ¼ 0.0072). Error bars indicate standard deviation (SD). **p < 0.01.
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rs2070600. No multi-colinearity was observed in these variables.
Stepwise multiple regression analysis indicated that haplotype 1
was the strongest factor for modulation of serum esRAGE levels
(standardized beta ¼ 0.296, p < 0.0001), followed by rs2070600
(standardized beta ¼ 0.246, p < 0.001) (Table 1). Likewise, sRAGE
levels were robustly determined by esRAGE levels (standardized
beta ¼ 0.806, p < 0.000001) as demonstrated by the same stepwise
multiple regression analysis (Supplementary Table 5).4. Discussion
In the present study, we demonstrated that genetic variants in
AGER are critical factors in the regulation of serum esRAGE levels
and that schizophrenia was signiﬁcantly associated with lower
esRAGE and sRAGE levels.Fig. 3. A: Serum sRAGE was signiﬁcantly decreased in schizophrenia. sRAGE levels were m
650.6 ± 348.0 pg/ml, Control: 839.4 ± 304.0 pg/ml, p ¼ 0.03). B: esRAGE/sRAGE ratio was dem
levels in both groups (Schizophrenia: 39.8%, Control: 37.3%, p ¼ 0.52). Error bars indicate s
Table 1
Multiple regression analysis of variables contributing to serum esRAGE levels.
Variables Adjusted R2
esRAGE Haplotype 1 0.139
rs2070600 (Gly82Ser)
Note:Number of subjects included in this analysis are composed of 104 schizophrenia aBy using direct sequencing, we identiﬁed 28 variants of AGER,
including 8 novel variants. AGER is located on chromosome 6p21.3,
which is a well described region that includes a number of Major
Histocompatibility Complex (MHC) related genes. Purcell, Shi and
Stefansson simultaneously found that these regions were associ-
ated with schizophrenia by genome-wide association study
(GWAS), and the result was conﬁrmed by a following larger GWAS
[19e22]. However, there have been no reports demonstrating as-
sociation between SNPs in AGER and schizophrenia. Likewise, we
found no AGER variants associatedwith schizophrenia as deﬁned by
the Bonferroni corrected p-value.
Regarding the association between serum esRAGE levels and
genetic variants in AGER, we newly found that a speciﬁc haplotype
composed of rs17846798, rs2071288, and a 63 bp deletion
(haplotype 1), all of which were in perfect linkage disequilibrium
(r2 ¼ 1), was strongly associated with a large decrease in serum
esRAGE levels. To the best of our knowledge, this is the ﬁrst study to
identify association of a functional haplotype of AGER with a sig-
niﬁcant decrease in serum esRAGE levels. Ohe et al. showed that
mutagenesis of the G-rich cis-elements in intron 9 resulted in a
dramatic increase in the esRAGE/RAGE ratio, via interaction with
hnRNP H [23]. Unfortunately, we found no variants in the region
examined by Ohe, but instead identiﬁed rs2071288, which is a
component of haplotype 1 and is located at a splice site in intron 9
(6 bp from exon 10), as being associated with a marked decrease
in serum esRAGE levels. We therefore put forward the possibility
that rs2071288 exerts an effect on alternative splicing and it is also
plausible that the expression of the RAGE protein itself was
inhibited by these functional mutations, resulting in lower serum
esRAGE levels in carriers of these variants. As for the other AGER
variants, we found that rs2070600, which is located in exon 3, was
strongly associated with decreased levels of serum esRAGE. This is
the most prominent SNP in AGER and has been predicted to be
‘probably damaging’ (PolyPhen-2; http://genetics.bwh.harvard.
edu/pph2/index.shtml). Previous reports have shown that the
G82S polymorphism of rs2070600 ampliﬁed the inﬂammatory
response and N-linked glycosylation of Asn81, leading to a
strengthening of the ligand binding ability of RAGE [24,25]. How-
ever the precise mechanisms by which this SNP mediates theeasured in schizophrenia (N ¼ 25) and control (N ¼ 49) individuals (Schizophrenia:
onstrated. Serum esRAGE levels accounted for approximately 40% of the serum sRAGE
tandard deviation (SD). *p < 0.05.
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zygous minor allele remain unclear and further studies will be
required.
In this study, we found a comparable esRAGE/sRAGE ratio in
schizophrenia and control groups, and this ratio was higher than
that reported in a previous study in which it was suggested that
esRAGE represented only a small proportion of the total circulating
soluble RAGE [26]. In addition, AGER risk variants determined
serum esRAGE levels as shown by multiple regression analysis.
Furthermore, sRAGE levels were robustly determined by esRAGE
levels. The combined data suggested that AGER risk variants were
the most critical regulator of sRAGE levels. It is therefore essential
to evaluate the presence of AGER variants to investigate the rela-
tionship between various diseases and circulating RAGE. Boso et al.
reported lower esRAGE levels in autistic spectrum disorder suf-
ferers compared with control subjects [27]. Two studies demon-
strated lower sRAGE levels in patients with schizophrenia relative
to healthy subjects [28,29]. Our results are consistent with previous
studies in that there were signiﬁcantly lower serum esRAGE levels
in schizophrenia relative to control subjects, taking into consider-
ation AGER variants. Furthermore, we found that sRAGE levels were
also signiﬁcantly decreased in schizophrenia. Although age was
inversely correlated with sRAGE in controls (data not shown), we
believe that the signiﬁcant decrease in sRAGE that was shown in
schizophrenia is plausible, since the proportion of subjects with
AGER risk variants, which is the most robust regulator of sRAGE,
was higher in controls (Supplementary Table 4). Combinedwith the
results of previous studies, our ﬁndings validated the reliability of
lower soluble RAGE levels shown in schizophrenia and provided
novel insights into the regulation of soluble RAGE including
esRAGE.
As with most studies of this nature, the present study suffers
from some limitation. First, we could not investigate membrane-
bound (full-length) RAGE (mb-FL-RAGE), which is another
possible factor in the regulation of soluble RAGE levels, should be
mentioned. Secondly, as sample sizes for each analysis were rela-
tively small, we had limited power to detect statistical signiﬁcance,
especially in the analysis of sRAGE.
In summary, this is the ﬁrst study to identify functional haplo-
type in AGER that are associated with marked decreases in esRAGE
serum levels. Statistical analysis controlling for confounding factors
indicated that these genetic variants contribute signiﬁcantly to
determination of the serum levels of esRAGE. Furthermore,
schizophrenic patients demonstrated vulnerability to carbonyl
stress as evidenced by lower serum esRAGE and sRAGE levels.
These ﬁndings should be validated in future research investigating
diseases associated with carbonyl stress.Conﬂict of interest
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